Mestrallet et al. focused on resistance mechanisms that limit anti-PD-1 efficacy in colorectal cancer (50% to 100% failure depending on mismatch repair status). bit.ly/49qWVm8
@sinaiimmuno.bsky.social
@gmestrallet.bsky.social @bhardwajlab.bsky.social
